Javaneh Lyons, MD, RhMSUS, MSc
Alaska Native Medical Center
Anchorage, AK, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Naomi Schlesinger, MD
University of Utah
Salt Lake City
Disclosure(s): ANI: Advisor or Review Panel Member (Terminated); Arthosi: Advisor or Review Panel Member (Ongoing); Horizon: Advisor or Review Panel Member (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing); Olatec: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Protalix: Advisor or Review Panel Member (Ongoing); Shanton: Advisor or Review Panel Member (Ongoing); SOBI: Advisor or Review Panel Member (Terminated)
Cheryl Barnabe, MD, FRCPC, MSc
University of Calgary
Calgary, AB, Canada
Disclosure(s): Fresenius Kabi: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, May 30, 2022); Janssen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, June 7, 2022); Pfizer: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, May 7, 2022)
Rosana Quintana, MD
Centro Regional de Enfermedades Autoinmunes y Reumáticas (CREAR),Grupo Oroño
Rosario, Argentina
Disclosure(s): No financial relationships with ineligible companies to disclose
Leanne Te Karu, PhD, PharmD
University of Auckland
Napier, New Zealand
Disclosure(s): No financial relationships with ineligible companies to disclose
Cheryl Barnabe, MD, FRCPC, MSc
University of Calgary
Calgary, AB, Canada
Disclosure(s): Fresenius Kabi: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, May 30, 2022); Janssen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, June 7, 2022); Pfizer: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, May 7, 2022)
Rosana Quintana, MD
Centro Regional de Enfermedades Autoinmunes y Reumáticas (CREAR),Grupo Oroño
Rosario, Argentina
Disclosure(s): No financial relationships with ineligible companies to disclose
Leanne Te Karu, PhD, PharmD
University of Auckland
Napier, New Zealand
Disclosure(s): No financial relationships with ineligible companies to disclose
Rheumatic diseases disproportionally affect indigenous populations worldwide, and inequalities in access to clinical services and treatment contribute to increased disease burden. This session will focus on the underlying reasons for the disproportionate rate of rheumatic diseases in the Indigenous population, obstacles in access to care, and creative strategies employed in different settings to overcome those barriers. Additionally, the session will highlight the underrepresentation of the Indigenous population in major research bodies and challenges in conducting culturally sensitive research, ways to extend current research efforts, and challenges for healthcare providers to partner with Indigenous populations to develop effective systems to overcome disparities and enable a pathway to health equity.
Virtual Moderator: Javaneh Lyons, MD, RhMSUS, MSc – Alaska Native Medical Center
Virtual Moderator: Naomi Schlesinger, MD – University of Utah
Virtual Speaker: Cheryl Barnabe, MD, FRCPC, MSc – University of Calgary
Virtual Speaker: Rosana Quintana, MD – Centro Regional de Enfermedades Autoinmunes y Reumáticas (CREAR),Grupo Oroño
Virtual Speaker: Leanne Te Karu, PhD, PharmD – University of Auckland
Virtual Moderator: Javaneh Lyons, MD, RhMSUS, MSc – Alaska Native Medical Center
Virtual Moderator: Naomi Schlesinger, MD – University of Utah
Virtual Panelist: Cheryl Barnabe, MD, FRCPC, MSc – University of Calgary
Virtual Panelist: Rosana Quintana, MD – Centro Regional de Enfermedades Autoinmunes y Reumáticas (CREAR),Grupo Oroño
Virtual Panelist: Leanne Te Karu, PhD, PharmD – University of Auckland